The aim of this thesis is to examine the competition patterns that exist between originators and generics by focusing on the articulations between regulation and incentives to innovate. Once the characteristics of regulation in pharmaceutical markets is reviewed in the first chapter and an...

Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...

We model how risk-neutral firms’ ability to obtain substantial private returns on marginal new technologies causes them to "reach for mediocrity" by investing in socially suboptimal projects, even in the presence of competition and new entrants. Focusing primarily on pharmaceutical innovation,...